http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3290513-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_15d42f684941d5b0617ca7764ebdff07
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14151
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14111
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00
filingDate 2005-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f0a4000b43394f4bb244d46e18968fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f61b14737c8a76226442661e2dcff340
publicationDate 2018-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-3290513-A1
titleOfInvention Compositions and methods to prevent aav vector aggregation
abstract Compositions and methods are provided for preparation of concentrated stock solutions of AAV virions without aggregation. Formulations for AAV preparation and storage are high ionic strength solutions (e.g. µ ∼500 mM) that are nonetheless isotonic with the intended target tissue. This combination of high ionic strength and modest osmolarity is achieved using salts of high valency, such as sodium citrate. AAV stock solutions up to 6.4x1013 vg/mL are possible using the formulations of the invention, with no aggregation being observed even after ten freeze-thaw cycles. The surfactant Pluronic® F68 may be added at 0.001% to prevent losses of virions to surfaces during handling. Virion preparations can also be treated with nucleases to eliminate small nucleic acid strands on virions surfaces that exacerbate aggregation.
priorityDate 2004-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6593123-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03097797-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9961643-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394420
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID773
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6251
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID232
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6235
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6335613
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7427
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3724
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23830
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226410796
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399858
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395486
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395791
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6274
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393714
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395485
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID107428
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393712
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394880
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399539
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID453
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393819

Total number of triples: 40.